BioGaia AB (publ) Cash Flow Conversion Efficiency
BioGaia AB (publ) cash flow conversion efficiency. Based on the latest financial reports, BioGaia AB (publ) (BIOG-B) has a cash flow conversion efficiency ratio of 0.046x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr50.77 Million ≈ $5.46 Million USD) by net assets (Skr1.10 Billion ≈ $118.50 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BioGaia AB (publ) (2002–2025)
Cash flow conversion efficiency of BioGaia AB (publ) from 2002 to 2025. This chart illustrates how BioGaia AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest BioGaia AB (publ) stock price today for real-time trading data and today's change.
BioGaia AB (publ) Cash Flow Conversion Ratio Explained
BioGaia AB (publ) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BioGaia AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioGaia AB (publ) ranked by their cash flow conversion efficiency. Also see BioGaia AB (publ) stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wuxi Paike New Materials Technology Co Ltd
SHG:605123
|
0.063x |
|
Shenzhen Noposion Agrochemicals Co Ltd
SHE:002215
|
-0.058x |
|
Sylvamo Corp
NYSE:SLVM
|
-0.010x |
|
Jiangsu Eazytec Co Ltd
SHG:688258
|
0.025x |
|
Hanall Biopharma
KO:009420
|
0.047x |
|
Akums Drugs and Pharmaceutical
NSE:AKUMS
|
0.346x |
|
FLEX LNG Ltd
F:0QQA
|
0.050x |
|
Preferred Bank
NASDAQ:PFBC
|
0.036x |
Annual Cash Flow Conversion Efficiency for BioGaia AB (publ) (2002–2025)
The table below shows the annual cash flow conversion efficiency of BioGaia AB (publ) from 2002 to 2025. Review BIOG-B free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr1.31 Billion ≈ $141.43 Million |
Skr306.57 Million ≈ $32.99 Million |
0.233x | +7.75% |
| 2024-12-31 | Skr1.72 Billion ≈ $185.52 Million |
Skr373.22 Million ≈ $40.16 Million |
0.216x | +3.14% |
| 2023-12-31 | Skr2.03 Billion ≈ $218.39 Million |
Skr425.96 Million ≈ $45.84 Million |
0.210x | +29.81% |
| 2022-12-31 | Skr1.97 Billion ≈ $212.26 Million |
Skr318.94 Million ≈ $34.32 Million |
0.162x | +36.82% |
| 2021-12-31 | Skr1.88 Billion ≈ $202.03 Million |
Skr221.88 Million ≈ $23.88 Million |
0.118x | -6.72% |
| 2020-12-31 | Skr1.75 Billion ≈ $187.92 Million |
Skr221.26 Million ≈ $23.81 Million |
0.127x | -56.48% |
| 2019-12-31 | Skr507.87 Million ≈ $54.66 Million |
Skr147.85 Million ≈ $15.91 Million |
0.291x | -19.22% |
| 2018-12-31 | Skr508.12 Million ≈ $54.68 Million |
Skr183.12 Million ≈ $19.71 Million |
0.360x | -24.90% |
| 2017-12-31 | Skr463.89 Million ≈ $49.92 Million |
Skr222.62 Million ≈ $23.96 Million |
0.480x | +34.69% |
| 2016-12-31 | Skr415.18 Million ≈ $44.68 Million |
Skr147.93 Million ≈ $15.92 Million |
0.356x | +20.03% |
| 2015-12-31 | Skr395.83 Million ≈ $42.60 Million |
Skr117.50 Million ≈ $12.64 Million |
0.297x | -17.76% |
| 2014-12-31 | Skr344.59 Million ≈ $37.08 Million |
Skr124.38 Million ≈ $13.39 Million |
0.361x | +45.81% |
| 2013-12-31 | Skr316.86 Million ≈ $34.10 Million |
Skr78.44 Million ≈ $8.44 Million |
0.248x | -66.30% |
| 2012-12-31 | Skr456.79 Million ≈ $49.16 Million |
Skr335.56 Million ≈ $36.11 Million |
0.735x | +132.47% |
| 2011-12-31 | Skr230.35 Million ≈ $24.79 Million |
Skr72.79 Million ≈ $7.83 Million |
0.316x | -14.17% |
| 2010-12-31 | Skr187.32 Million ≈ $20.16 Million |
Skr68.97 Million ≈ $7.42 Million |
0.368x | +11.31% |
| 2009-12-31 | Skr161.12 Million ≈ $17.34 Million |
Skr53.29 Million ≈ $5.73 Million |
0.331x | +128.07% |
| 2008-12-31 | Skr132.42 Million ≈ $14.25 Million |
Skr19.20 Million ≈ $2.07 Million |
0.145x | +170.52% |
| 2007-12-31 | Skr94.91 Million ≈ $10.21 Million |
Skr5.09 Million ≈ $547.55K |
0.054x | +580.80% |
| 2006-12-31 | Skr74.53 Million ≈ $8.02 Million |
Skr-831.00K ≈ $-89.43K |
-0.011x | +91.97% |
| 2005-12-31 | Skr71.78 Million ≈ $7.72 Million |
Skr-9.97 Million ≈ $-1.07 Million |
-0.139x | -155.28% |
| 2004-12-31 | Skr91.50 Million ≈ $9.85 Million |
Skr22.99 Million ≈ $2.47 Million |
0.251x | +27.74% |
| 2003-12-31 | Skr114.85 Million ≈ $12.36 Million |
Skr22.59 Million ≈ $2.43 Million |
0.197x | -14.88% |
| 2002-12-31 | Skr127.99 Million ≈ $13.77 Million |
Skr29.57 Million ≈ $3.18 Million |
0.231x | -- |
About BioGaia AB (publ)
BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well … Read more